Abbott India is currently trading at Rs. 1485.00, up by 14.65 points or 1.00% from its previous closing of Rs. 1470.35 on the BSE.
The scrip opened at Rs. 1486.10 and has touched a high and low of Rs. 1519.65 and Rs. 1486.10 respectively. So far 1974 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1650.00 on 06-Sep-2012 and a 52 week low of Rs. 1306.00 on 25-Mar-2013.
Last one week high and low of the scrip stood at Rs. 1544.00 and Rs. 1411.40 respectively. The current market cap of the company is Rs. 3172.52 crore.
The promoters holding in the company stood at 74.99% while Institutions and Non-Institutions held 6.64% and 18.37% respectively.
Abbott India has decided to put on back burner the plans for sale and transfer of or other appropriate restructuring of the proprietary pharmaceuticals division (PPD) of the company. The company’s board of directors at their meeting held on June 3, 2013, decided the same. In the year ended December 31, 2012, the PPD business accounted for sales of Rs 76.22 crore which constituted of 4.73% of the net sales of Rs 1613.09 crore of the company.
Abbott India is healthcare company that discovers, develops, manufactures and markets innovative products and services. In 1888 a young Chicago physician, Dr Wallace Calvin Abbott founded Abbott Laboratories.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: